See how our client utilized Rapid Payer Response™ (RPR) to gain invaluable Payer insight into the Pricing and Market Access acceptability of their novel product within 3 Weeks.
A client was in the process of developing a treatment for osteoarthritis (OA), where currently there are no DMOAD products approved. To better assess the acceptability of their product, they leveraged Rapid Payer Response (RPR) to elicit insights from both the Medicare and the Commercial perspective by engaging with a large sample of key payers and related stakeholders.
Download to learn more.
Robust Review: Pricing & Market Access
PDF File: 471.3 KB
Address:
51 John F Kennedy Parkway
1st Floor West
Short Hills
New jersey
07078
USA